10-Q: Vitro BioPharma Faces Going Concern Amid Rising Losses

Vitro BioPharma reported a significant increase in its quarterly net loss and a worsening working capital deficit, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended July 31, 2025, increased by 1,042% to $1,698,538, compared to a loss of $149,080 in the prior year, primarily due to the absence of large non-recurring gains from debt extinguishment and derivative liabilities seen in 2024.
• For the nine months ended July 31, 2025, net loss decreased by 23% to $6,011,986, compared to $7,837,185 in the prior year, mainly due to the absence of a large write-off of offering costs and reduced interest expense, partially offset by a loss on debt extinguishment.
• Total revenue for the three months increased by 90% to $608,643, and for the nine months, it increased by 19% to $1,570,101, driven by AlloRx Stem Cells and research and development products.
• The company's cash balance significantly decreased by 69% from $571,360 at October 31, 2024, to $175,081 at July 31, 2025.
• The working capital deficit worsened by approximately $5.1 million, reaching $14.2 million as of July 31, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, citing accumulated deficit, net losses, and insufficient working capital.
• The commencement of planned clinical trials for PTHS and Long COVID is contingent on securing an estimated $4 million to $6 million in additional working capital.
• Internal control over financial reporting was deemed not effective as of July 31, 2025.

Sentiment

Score: 3

Explanation: While revenue growth is positive, the significant increase in three-month net loss, worsening working capital deficit, and the explicit 'going concern' warning indicate severe financial distress and high operational risk. The reliance on future capital raises for core operations and clinical trials is a major concern, compounded by ineffective internal controls.

Positives

• Total revenue increased by 90% for the three months ended July 31, 2025, and by 19% for the nine months ended July 31, 2025, compared to the prior year periods.
• Sales of AlloRx Stem Cells to foreign third-party clinics increased by 129% for the three months and 28% for the nine months ended July 31, 2025.
• Gross profit percentage improved to 89% for the three months ended July 31, 2025, from 80% in the prior year period.
• Selling, General and Administrative (SG&A) expenses decreased by 5% for the three months and 8% for the nine months ended July 31, 2025.
• Research and Development (R&D) expenses decreased by 5% for the three months and 1% for the nine months ended July 31, 2025.
• Interest expense decreased by 56% for the three months and 68% for the nine months ended July 31, 2025.
• Net cash used in operating activities decreased by 21% for the nine months ended July 31, 2025, indicating improved operational cash burn.
• A gain on forgiveness of debt of $343,938 was recognized during the nine months ended July 31, 2025, from the renegotiation of the 2021 Series Convertible Notes Payable.

Negatives

• Net loss for the three months ended July 31, 2025, increased significantly by 1,042% to $1,698,538, compared to $149,080 in the prior year, primarily due to the absence of large non-recurring gains from debt extinguishment and derivative liabilities in 2024.
• The working capital deficit worsened by approximately $5.1 million, reaching $14.2 million as of July 31, 2025, compared to $9.1 million at October 31, 2024.
• Cash balance decreased by 69% from $571,360 at October 31, 2024, to $175,081 at July 31, 2025.
• The accumulated deficit increased to $43,961,679 as of July 31, 2025.
• A loss on extinguishment of debt of $1,235,000 was recorded for the nine months ended July 31, 2025.
• Fitore product sales ceased, and InfiniVive product sales decreased by 11% for the nine-month period ended July 31, 2025.
• Management concluded that disclosure controls and procedures were not effective due to ineffective internal control over financial reporting as of July 31, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to an accumulated deficit of $43.9 million, net losses of $6.0 million for the nine months, a working capital deficit of $14.2 million, and insufficient cash ($175,081) to support operations for the next 12 months.
• The company is highly dependent on raising additional capital through debt or equity financings, collaborations, or licensing arrangements, with no assurance of success.
• Future equity or convertible debt financings will likely result in significant dilution to existing stockholders.
• Failure to secure sufficient capital may compel the company to curtail part or all of its ongoing operations.
• Commencement of planned clinical trials for AlloRx Stem Cell therapy in PTHS and Long COVID is pending receipt of an estimated $4 million to $6 million in additional working capital.
• Risks are associated with maintaining, expanding, and protecting intellectual property rights and defending against infringement claims.
• Uncertainty exists in obtaining regulatory approval for product candidates.
• The company faces competition from existing and emerging therapies in the biotechnology industry.
• The effectiveness of internal control over financial reporting was deemed not effective, posing risks to financial reporting reliability.

Future Outlook

Management expects SG&A and R&D expenses to increase significantly in the future, particularly with the commencement of clinical trials. AlloRx Stem Cell sales internationally are anticipated to grow. The company expects to continue reporting losses until its subsidiaries improve operations or product candidates are commercialized. Clinical trials for PTHS and Long COVID are planned for late 2025, contingent on securing $4 million to $6 million in additional working capital. The company plans to raise further capital through equity or debt offerings and pursue strategic alliances to increase revenue and achieve profitable operations. Additional clean rooms for manufacturing are also planned, with an estimated cost of $0.3 million to $0.5 million.

Management Comments

• "We expect to continue reporting losses until such time, if ever, we can improve the operation of our newly acquired subsidiaries and/or commercialize one or more of our product candidates and generate sales sufficient to offset our operating costs and expenses and interest expenses."
• "We expect AlloRx Stem Cell sales internationally to increase over the next year as these products expand into additional foreign third-party clinics and medical centers and our current foreign third-party clinics and medical center customers increase their total monthly patients as international travel continues to pick back up."
• "Our ability to continue as a going concern is dependent upon our ability to raise additional funds through debt or equity financings and our ability to further implement our business plan and generate additional revenue."
• "We do not anticipate commencing any clinical trials of our AlloRx Stem Cell therapy unless and until we receive substantial additional capital, as costs are estimated to be $4 million to $6 million to commence our contemplated Phase 1/2a clinical trials for PTHS and Long COVID, depending on whether we commence one or both trials."

Industry Context

Vitro BioPharma operates in the dynamic biotechnology sector, focusing on regenerative medicine, autoimmune diseases, and inflammatory disorders, with supplementary activities in research services and cosmeceuticals. The company's emphasis on AlloRx Stem Cells and exosome therapy aligns with the growing interest in advanced biological treatments. Its pursuit of FDA IND applications for clinical trials in PTHS and Long COVID indicates an effort to validate its therapies within a regulated market, which is crucial for broader market acceptance and potential valuation increases. The strategic decision to limit Fitore product sales suggests a focus shift towards higher-value biotech segments. The significant capital requirements for clinical trials are typical for early-stage biotech firms, highlighting the high-risk, high-reward nature of the industry.

Comparison to Industry Standards

• The company's financial position, characterized by a substantial accumulated deficit, working capital deficit, and explicit going concern warning, is indicative of an early-stage biotechnology company, but the magnitude of these deficits suggests a more distressed financial state compared to many well-funded peers.
• Gross profit percentages of 89% (three months) and 81% (nine months) are strong, suggesting favorable unit economics for its products, which is a positive indicator within the biotech industry where product margins can be high once commercialized.
• The relatively low R&D spending compared to the estimated $4 million to $6 million needed for planned clinical trials highlights a significant funding gap, which is a common challenge for small biotech firms but also a critical bottleneck for advancing product candidates.

Corporate Governance

Legal Proceedings

• No legal proceedings, government actions, administrative actions, investigations, or claims are currently pending or threatened against the company or its officers and directors in which the company is adverse.

Related Party Transactions

• Product sales to Dr. Jack Zamora (former CEO and 30% stockholder) amounted to $13,500 for the three months and $31,500 for the nine months ended July 31, 2025. Dr. Zamora owed the company $15,750 in accounts receivable as of July 31, 2025.
• The company leases office and lab space from an entity controlled by the spouse of the Chief Science Officer at $5,645 per month, with no past due rent as of July 31, 2025.
• The company owed its CEO $22,610 in travel expense reimbursements as of July 31, 2025.
• Unsecured 6% Note Payable Related Party had a principal balance of $1,221,958 as of July 31, 2025, with an original maturity date of December 31, 2025, for which an extension is being negotiated.
• Unsecured 4% Note Payable Related Party had a principal balance of $767,288 as of July 31, 2025, with an original maturity date of December 31, 2025, for which an extension is being negotiated.
• The 2021 Series Convertible Note Related Party, with an original principal balance of $480,000, was fully paid on April 30, 2025, after renegotiation resulted in a $343,938 gain on forgiveness of debt.
• John Evans, a former CFO, has $229,667 in deferred and accrued compensation under a consulting agreement that expires December 1, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from anticipated future equity or convertible debt financings, and the increased accumulated deficit and working capital deficit negatively impact shareholder equity. The going concern warning poses substantial risk to investment value.
• Employees may see increased headcount in research and development and management if sufficient capital is raised, but also face the risk of operational curtailment if funding is not secured.
• Customers can expect continued supply of AlloRx Stem Cells and research and development products, with anticipated international growth, while Fitore product availability will be limited.
• Creditors are impacted by the company's active management and renegotiation of debt, including related-party notes, and new secured convertible notes provide security to recent investors.
• Regulatory bodies are engaged through the company's pursuit of FDA IND applications for product development, indicating adherence to regulatory processes.

Next Steps

• Raise additional capital through public/private equity or debt offerings to fund operations and clinical trials.
• Implement initiatives to increase revenue generation through diversified product and service offerings.
• Pursue strategic alliances for overall growth and development.
• Commence planned Phase 1/2a clinical trials for PTHS and Long COVID in late 2025, contingent on securing $4 million to $6 million in working capital.
• Advance preclinical and clinical development of other research programs and product candidates.
• Expand the intellectual property portfolio.
• Hire additional personnel in research, manufacturing, regulatory, clinical development, and management.
• Seek regulatory approval for product candidates that successfully complete clinical development.
• Expand manufacturing capabilities, including adding clean rooms (estimated $0.3M-$0.5M).
• Improve operational, financial, and management systems.
• Address the identified ineffective internal control over financial reporting.
• Negotiate extensions for Unsecured 6% and 4% Notes Payable Related Party, which mature December 31, 2025.
• Renegotiate remaining 2024 Series notes for longer maturity dates.
• Assess and implement ASU 2023-07 (Segment Reporting) by the fiscal year end of October 31, 2025.
• Adopt ASU 2024-03 (Disaggregation of Income Statement Expenses) for the period beginning November 1, 2027.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial working capital deficit of $14.2 million, a rapidly dwindling cash balance of $175,081, and an explicit 'going concern' warning from management. While revenue growth is present, it is insufficient to offset significant operating losses and interest expenses, leading to a 1,042% increase in net loss for the most recent quarter. The company's ability to fund its core operations and critical clinical trials is entirely dependent on future capital raises, which carry substantial dilution risk for existing shareholders and no guarantee of success. Furthermore, the disclosure of ineffective internal controls over financial reporting adds another layer of operational risk and uncertainty. These factors collectively point to a highly precarious financial position with significant downside risk for investors.

Keywords

Biotechnology, Stem Cell Therapy, AlloRx, InfiniVive MD, Regenerative Medicine, Autoimmune Diseases, Inflammatory Disorders, Clinical Trials, SEC Filing, 10-Q, Financial Report, Convertible Notes, Warrants, Going Concern, Capital Raise, PTHS, Long COVID, Cosmeceuticals